Liraglutide
FDA-approved daily GLP-1 (a gut hormone signal for fullness and blood-sugar handling) medicine — Victoza / Saxenda.
What it's for
FDA-approved daily GLP-1 (a gut hormone signal for fullness and blood-sugar handling) medicine — Victoza / Saxenda.
What it's for
Liraglutide is a once-daily GLP-1 medicine (a gut hormone signal for fullness and blood-sugar handling). Brand versions include Victoza and Saxenda — each with its own approved uses for type 2 diabetes or weight management.
What it does for the body
Victoza: type 2 diabetes blood-sugar control and CV risk reduction in labeled T2D populations. Saxenda: chronic weight management. Doses and brands differ. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
GLP-1 (a gut hormone signal for fullness and blood-sugar handling) receptors (lock-and-key landing spots on cells) activating its target pathway increases the body's release of insulin when blood sugar is high, lowers glucagon, slows how quickly food leaves the stomach, and reduces appetite. Think of it like turning up a dimmer switch on the body's natural "I'm full / handle sugar after meals" signal.
Research context
Bottom line for readers: Liraglutide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Liraglutide — FDA.gov search
- ClinicalTrials.gov search: Liraglutide — U.S. clinical trials registry
- Drugs@FDA search: Liraglutide — FDA drug database (if approved)
- PubMed search: Liraglutide — NCBI PubMed
- PubMed Central search: Liraglutide — NCBI PMC